Data accompanying the research on: Does Betamethasone therapy impact fetal multivessel doppler parameters?

This was a prospective cohort study. During March 2018–March 2019, 27 singleton pregnancies between 28 and 34 gestational weeks with a diagnosis threat of preterm birth were included prospectively. To be eligible, patients had to have received betamethasone and a loading dose of nifedipine for tocolysis, followed by hydration and maintenance nifedipine therapy for 48 h. Betamethasone (Celestone Cronodose, Schering-Plough, İstanbul, Turkey) was administered as two doses of 12 mg each, administered 24 h apart. Fetuses, who had intrauterine growth restriction (IUGR), oligohydramnios, polyhydramnios, or fetal anomaly were excluded from the study. Other maternal indications for exclusion were: preeclampsia, eclampsia, HELLP syndrome, premature preterm rupture of membranes, placenta previa, or any chronic maternal disease. Patients with diabetes mellitus (gestational or pregestational) were not included in the study. We prospectively evaluated fetal main pulmonary artery (MPA), left and right pulmonary artery (PA), left myocardial performance index (MPI, TEI index), tricuspid valve (TV), umbilical artery (UmA), middle cerebral artery (MCA), and ductus venous (DV) parameters before and at 48 h and 7 days after steroid administration. The Doppler indices of interest included Peak Systolic Velocity (PSV), Resistance Index (RI), Pulsatility Index (PI), Systolic/Diastolic ratio (S/D ratio), Acceleration Time/Ejection Time Ratio (AT/ET ratio) (MPA), E/A ratio (TV), left ventricle TEI index parameters (isovolumetric contraction time (ICT), isovolumetric relaxation time (IRT), ejection time (ET), and DV A wave.

本研究为一项前瞻性队列研究。2018年3月至2019年3月期间，前瞻性纳入27例孕28~34周、诊断为早产先兆的单胎妊娠孕妇。纳入标准如下：患者需接受倍他米松与负荷剂量硝苯地平行宫缩抑制治疗，随后补液并维持硝苯地平治疗48小时。倍他米松（商品名：Celestone Cronodose，先灵葆雅（Schering-Plough）土耳其伊斯坦布尔分厂生产）给药方案为每次12mg，共2剂，间隔24小时给药。排除标准包括：胎儿存在宫内生长受限（intrauterine growth restriction, IUGR）、羊水过少、羊水过多或胎儿畸形者；母体排除指征为子痫前期、子痫、HELLP综合征、早产胎膜早破、前置胎盘，或任何慢性母体疾病；合并糖尿病（妊娠期糖尿病或孕前糖尿病）的患者亦不纳入本研究。本研究前瞻性评估了类固醇给药前、给药后48小时及7天时的胎儿主肺动脉（main pulmonary artery, MPA）、左/右肺动脉（pulmonary artery, PA）、左心室心肌做功指数（left myocardial performance index, MPI，又称TEI指数）、三尖瓣（tricuspid valve, TV）、脐动脉（umbilical artery, UmA）、大脑中动脉（middle cerebral artery, MCA）及静脉导管（ductus venous, DV）参数。关注的多普勒指数包括：峰值收缩速度（Peak Systolic Velocity, PSV）、阻力指数（Resistance Index, RI）、搏动指数（Pulsatility Index, PI）、收缩期/舒张期比值（Systolic/Diastolic ratio, S/D比值）、主肺动脉相关的加速时间/射血时间比值（Acceleration Time/Ejection Time Ratio, AT/ET比值）、三尖瓣相关的E/A比值、左心室TEI指数相关参数（等容收缩时间isovolumetric contraction time, ICT、等容舒张时间isovolumetric relaxation time, IRT、射血时间ejection time, ET）及静脉导管A波。